Study

Overview

Official Title: A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer

This study correlated changes from baseline in Ki-67, an immunohistochemical marker of cell proliferation, with changes from baseline in tumor uptake of 3'-deoxy-3'[18F]-fluorothymidine (18F-FLT) following the first cycle of treatment with standard of care neo-adjuvant therapy in participants with breast cancer.

Study Type:

Interventional

Study Phase:

Phase 2

Enrollment:

46

Study Start Date:

April 2010

Study Completion Date:

December 2011

Primary Completion Date:

May 2011

Eligibility

Ages Eligible for Study:

35 years to 75 years

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

CRITERIA

Inclusion Criteria:

Has newly-diagnosed stage IIB/IIIA/IIIB locally advanced breast cancer
Is eligible for pre-operative (neo-adjuvant) chemotherapy

Exclusion Criteria:

Has a contraindication to magnetic resonance imaging (MRI)
Any condition that would limit ability to undergo MRI or PET scans
Is a nursing mother
Has moderate to end-stage renal disease and is not on dialysis or has renal failure on chronic dialysis

Locations

No Contacts or Locations in US/Canada Provided

Results

No Study Results Posted

Study Detail

18F-FLT-PET in Breast Cancer (MK-0000-139)

Overview

Eligibility

CRITERIA

Locations

Results